Perimenopause

What it is

Perimenopause is the transitional phase before menopause during which ovarian hormone production becomes irregular and declining, affecting roughly 1.5 million Canadian women at any given time. Also called the menopausal transition, perimenopause typically begins in the mid-40s and lasts an average of 4 to 8 years, though the range spans 2 to 12 years and onset can occur as early as the late 30s. It ends — and menopause begins — only once 12 consecutive months without a menstrual period have passed, meaning the boundary is confirmed in retrospect.

Perimenopause is frequently the most symptomatic phase of the entire menopause transition. The hormonal volatility of this stage, rather than the sustained low estrogen of postmenopause, drives many of its most disruptive symptoms: hot flashes, mood changes, sleep disruption, and cognitive fog. It is a normal biological process, but one that can substantially affect quality of life and warrants proper clinical recognition. The Society of Obstetricians and Gynaecologists of Canada (SOGC) recognizes perimenopause as a distinct clinical stage requiring individualized assessment and management.

Causes and mechanism

Perimenopause is caused by the gradual decline in the number and quality of ovarian follicles — the structures responsible for producing estrogen and releasing eggs.

Three interconnected mechanisms drive the transition:

Mechanism	What happens	Clinical effect
Declining ovarian reserve	Fewer viable follicles remain; estrogen output becomes erratic	Wide swings in estrogen — sometimes very high, sometimes very low
Progesterone deficiency	Ovulation becomes inconsistent; the corpus luteum fails to form reliably	Reduced progesterone in the luteal phase; relative estrogen dominance; heavier or irregular bleeding
Rising FSH	The pituitary gland increases follicle-stimulating hormone output to compensate for poor ovarian response	Elevated FSH is a laboratory marker of advancing perimenopause

Several factors influence when perimenopause begins. Genetics is the strongest predictor — a mother's age at menopause is the best guide to a daughter's. Cigarette smoking is associated with earlier onset by 1 to 2 years. Chemotherapy, pelvic radiation, and prior ovarian surgery can all accelerate the transition.

Symptoms and diagnosis

Perimenopausal symptoms stem from erratic, fluctuating hormone levels rather than the consistently low estrogen seen after menopause. This distinction matters clinically: the unpredictable rises and falls in estrogen — particularly sudden drops — trigger vasomotor and mood symptoms more intensely than a stable low-estrogen state does.

Menstrual changes are often the first sign: cycles may shorten or lengthen, flow may become heavier or lighter, and periods may be skipped entirely.

Vasomotor symptoms — hot flashes and night sweats — affect up to 80% of women during the transition and are the most commonly reported complaint.

Psychological and cognitive symptoms include mood changes, irritability, anxiety, low mood, brain fog, and difficulty concentrating. These are frequently underattributed to perimenopause in clinical settings.

Sleep disruption, breast tenderness, joint aches, headaches, changes in libido, and early genitourinary symptoms (vaginal dryness, urinary urgency) round out the picture.

Diagnosis in Canada follows a clinical approach:

• In women over 45 with characteristic symptoms and menstrual irregularity, perimenopause is a clinical diagnosis. Routine hormone testing is not required, as a single FSH or estradiol result can be misleading given the extreme day-to-day variability of hormone levels during this stage.
• In women under 45 with possible perimenopausal symptoms, FSH and estradiol testing — available through LifeLabs or Dynacare across most provinces — is recommended to assess whether ovarian function is declining earlier than expected.
• Serial testing or clinical reassessment over time is more informative than a single snapshot.

Treatment options

Treatment during perimenopause targets symptom relief and, where appropriate, longer-term protection against the bone and cardiovascular consequences of estrogen deficiency.

Hormone therapy (HT) is the most effective treatment for perimenopausal symptoms. During perimenopause specifically, estrogen combined with cyclical progestogen is the standard regimen — the progestogen protects the endometrium and maintains a regular withdrawal bleed. Transdermal estrogen (patch or gel) is generally preferred over oral estrogen because it carries a lower risk of venous thromboembolism. The SOGC and The Menopause Society both support initiating HT in symptomatic perimenopausal women who have no contraindications.

Contraception remains necessary throughout perimenopause. Women are still fertile until menopause is confirmed, and the combined oral contraceptive pill can serve a dual purpose — managing symptoms while providing reliable contraception in eligible women.

Non-hormonal prescription options include fezolinetant (a neurokinin B antagonist approved by Health Canada in 2023 for moderate-to-severe vasomotor symptoms), venlafaxine (an SNRI with moderate efficacy for hot flashes), and gabapentin (particularly useful for night sweats).

Lifestyle measures with evidence behind them include regular aerobic and resistance exercise, mindfulness-based stress reduction (shown to reduce hot flash frequency and improve mood), and avoiding common vasomotor triggers such as caffeine, alcohol, spicy foods, and hot environments.

Canadian patients seeking virtual care for perimenopause management can compare options including Felix, Cleo, Maple, Phoenix, and others — services vary by province and formulary coverage.

When to see a clinician in Canada

Seek assessment if you are in your 40s and experiencing new or worsening menstrual irregularity, hot flashes or night sweats disrupting sleep or daily function, mood changes or anxiety without an obvious cause, or cognitive changes affecting work or relationships. Very heavy periods warrant investigation to exclude structural pathology such as fibroids or endometrial changes before attributing bleeding to perimenopause alone.

If symptoms begin before age 45, earlier clinical review is important. Early perimenopause carries greater long-term implications for bone density and cardiovascular health, and may warrant earlier hormonal intervention. Provincial pharmacare coverage for HT varies — British Columbia, Ontario, and Quebec formularies cover several estrogen and progestogen products, but patients should confirm coverage with their pharmacist or provincial drug benefit program.

Limitations and open questions

Research is still emerging on several aspects of perimenopause. The relationship between perimenopausal hormonal fluctuations and long-term cognitive health — including dementia risk — remains an active area of investigation, with no definitive conclusions yet. The optimal timing and duration of hormone therapy initiated during perimenopause (as opposed to postmenopause) is not fully established, and individualized decision-making remains the standard. Health Canada has not yet issued specific guidance on the use of compounded bioidentical hormones during perimenopause, and evidence for their safety and efficacy relative to regulated products is limited. The mechanisms linking perimenopausal sleep disruption to cardiovascular risk are incompletely understood. For women with premature ovarian insufficiency (POI), the evidence base for long-term HT is extrapolated largely from perimenopausal and postmenopausal data rather than POI-specific trials.